Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4796587
Max Phase: Preclinical
Molecular Formula: C35H58N8O8
Molecular Weight: 718.90
Molecule Type: Unknown
Associated Items:
ID: ALA4796587
Max Phase: Preclinical
Molecular Formula: C35H58N8O8
Molecular Weight: 718.90
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)O
Standard InChI: InChI=1S/C35H58N8O8/c1-21(2)19-29(35(50)51)43-34(49)28(20-22-13-15-23(44)16-14-22)42-33(48)26-10-4-3-9-24(38)30(45)39-25(11-5-7-17-36)31(46)41-27(32(47)40-26)12-6-8-18-37/h13-16,21,24-29,44H,3-12,17-20,36-38H2,1-2H3,(H,39,45)(H,40,47)(H,41,46)(H,42,48)(H,43,49)(H,50,51)/t24-,25-,26-,27-,28-,29-/m0/s1
Standard InChI Key: YLJSFXPUYHOBFS-AQRCPPRCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 718.90 | Molecular Weight (Monoisotopic): 718.4378 | AlogP: -0.35 | #Rotatable Bonds: 17 |
Polar Surface Area: 281.09 | Molecular Species: ZWITTERION | HBA: 10 | HBD: 10 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.84 | CX Basic pKa: 10.42 | CX LogP: -3.60 | CX LogD: -5.80 |
Aromatic Rings: 1 | Heavy Atoms: 51 | QED Weighted: 0.09 | Np Likeness Score: 0.44 |
1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P. (2021) Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic., 64 (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726] |
Source(1):